Actively Recruiting
A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)
Led by Pfizer · Updated on 2026-05-14
87
Participants Needed
43
Research Sites
211 weeks
Total Duration
On this page
Sponsors
P
Pfizer
Lead Sponsor
B
Bristol-Myers Squibb
Collaborating Sponsor
AI-Summary
What this Trial Is About
The main purpose of the study is to understand how safe and tolerable is elranatamab when given along with iberdomide. There are 2 parts to this study. Part 1 will look at how safe and tolerable is elranatamab when given with iberdomide. Part 2 will look at the correct amount of this combination that can be given to patients with relapsed or refractory multiple myeloma. Myeloma is a type of cancer that begins in plasma cells (white blood cells that produce antibodies). Refractory means a disease or condition that does not respond to treatment. Relapsed means the return of a disease after a period of improvement. All study medicines are given in cycles that last 28 days. Everyone taking part in this study will receive elranatamab as a shot under the skin. Iberdomide will be taken by mouth once a day for 21 days over a 28-day cycle. Participants will receive study medicine until: * their disease progresses or, * they experience unacceptable side effects or, * they choose to no longer take part in the study. The study will look at the experiences of people receiving the study medicines. This will help see if the study medicines are safe and can be used for multiple myeloma treatment.
CONDITIONS
Official Title
A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Prior diagnosis of multiple myeloma as defined by IMWG criteria
- Measurable disease based on IMWG criteria including serum or urine M-protein or abnormal serum immunoglobulin
- Part 1: Received 2-4 prior lines of therapy including at least 1 immunomodulatory drug and 1 proteasome inhibitor
- Part 2: Received 1-3 prior lines of therapy including at least 1 immunomodulatory drug and 1 proteasome inhibitor
- ECOG performance status of 0 or 1
- Resolved acute effects of prior therapy to baseline severity or CTCAE Grade 1 or less
You will not qualify if you...
- Plasma cell leukemia, smoldering multiple myeloma, Waldenstr51m's macroglobulinemia, amyloidosis, or POEMS syndrome
- Impaired cardiovascular function or significant cardiovascular diseases
- Stem cell transplant within 12 weeks before enrollment or active graft versus host disease
- Active, uncontrolled bacterial, fungal, or viral infections
- Any other active cancer within 3 years except treated basal cell or squamous cell skin cancer or carcinoma in situ
- Previous treatment with BCMA-directed or CD3 redirecting therapy
- Previous treatment with iberdomide (CC-220) or mezigdomide
- Use of strong CYP3A4/5 inhibitors or inducers within 2 weeks before dosing and during the study
- Use of investigational products within 30 days before the first dose
- Unable or unwilling to receive required thromboembolism prevention
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 43 locations
1
Sylvester Comprehensive Cancer Center - The Lennar Foundation Medical Center
Coral Gables, Florida, United States, 33146
Not Yet Recruiting
2
University of Miami Hospital and Clinics Deerfield Beach
Deerfield Beach, Florida, United States, 33442
Not Yet Recruiting
3
Sylvester Comprehensive Cancer Center- Doral
Doral, Florida, United States, 33166
Not Yet Recruiting
4
Sylvester Comprehensive Cancer Center
Miami, Florida, United States, 33136
Not Yet Recruiting
5
University of Miami Hospital and Clinics
Miami, Florida, United States, 33136
Not Yet Recruiting
6
Sylvester Comprehensive Cancer Center Kendall
Miami, Florida, United States, 33176
Not Yet Recruiting
7
Sylvester Comprehensive Cancer Center Plantation
Plantation, Florida, United States, 33324
Not Yet Recruiting
8
Emory University Hospital Midtown
Atlanta, Georgia, United States, 30308
Actively Recruiting
9
Emory University Hospital
Atlanta, Georgia, United States, 30322
Actively Recruiting
10
Winship Cancer Institute
Atlanta, Georgia, United States, 30322
Actively Recruiting
11
Indiana CTSI Clinical Research Center (ICRC)
Indianapolis, Indiana, United States, 46202
Actively Recruiting
12
Indiana University Health University Hospital
Indianapolis, Indiana, United States, 46202
Actively Recruiting
13
Indiana University Melvin and Bren Simon Comprehensive Cancer Center (IUSCCC)
Indianapolis, Indiana, United States, 46202
Actively Recruiting
14
University of Maryland
Baltimore, Maryland, United States, 21201
Actively Recruiting
15
Brigham and Women's Hospital
Boston, Massachusetts, United States, 02115
Actively Recruiting
16
Dana-Farber Cancer Institute
Boston, Massachusetts, United States, 02215
Actively Recruiting
17
Dana-Farber Cancer Institute - Chestnut Hill
Newton, Massachusetts, United States, 02459
Actively Recruiting
18
University of Massachusetts Chan Medical School
Worcester, Massachusetts, United States, 01655
Not Yet Recruiting
19
Methodist Hospital
Omaha, Nebraska, United States, 68114
Actively Recruiting
20
Oncology Hematology West P.C. dba Nebraska Cancer - Methodist
Omaha, Nebraska, United States, 68114
Actively Recruiting
21
Oncology Hematology West P.C. dba Nebraska Cancer Specialists
Omaha, Nebraska, United States, 68130
Actively Recruiting
22
Dartmouth Hitchcock Medical Center
Lebanon, New Hampshire, United States, 03756
Actively Recruiting
23
MSK Basking Ridge
Basking Ridge, New Jersey, United States, 07920
Actively Recruiting
24
MSK Monmouth
Middletown, New Jersey, United States, 07748
Actively Recruiting
25
MSK Bergen
Montvale, New Jersey, United States, 07645
Actively Recruiting
26
MSK Commack
Commack, New York, United States, 11725
Actively Recruiting
27
MSK Westchester
Harrison, New York, United States, 10604
Actively Recruiting
28
Memorial Sloan Kettering Cancer Center - Investigational Drug Service Pharmacy
Long Island City, New York, United States, 11101
Actively Recruiting
29
Memorial Sloan Kettering Cancer Center - David H. Koch Center for Cancer Care (74th Street).
New York, New York, United States, 10021
Actively Recruiting
30
Memorial Sloan Kettering Cancer Center - Main Campus
New York, New York, United States, 10065
Actively Recruiting
31
MSK Nassau
Uniondale, New York, United States, 11553
Actively Recruiting
32
Fred Hutchinson Cancer Center
Seattle, Washington, United States, 98109
Not Yet Recruiting
33
University of Washington
Seattle, Washington, United States, 98195
Not Yet Recruiting
34
Medical College of Wisconsin
Milwaukee, Wisconsin, United States, 53226
Not Yet Recruiting
35
Liverpool Hospital
Liverpool, New South Wales, Australia, 2170
Actively Recruiting
36
Calvary Mater Newcastle
Waratah, New South Wales, Australia, 2298
Actively Recruiting
37
Townsville University Hospital
Douglas, Queensland, Australia, 4814
Actively Recruiting
38
Epworth Freemasons
East Melbourne, Victoria, Australia, 3002
Actively Recruiting
39
Epworth Hospital
Richmond, Victoria, Australia, 3121
Actively Recruiting
40
Slade Pharmacy
Richmond, Victoria, Australia, 3121
Actively Recruiting
41
Dr. Everett Chalmers Regional Hospital
Fredericton, New Brunswick, Canada, E3B 5N5
Actively Recruiting
42
CIUSSS de l'Est-de-l'Île-de-Montréal
Montreal, Quebec, Canada, H1T 2M4
Actively Recruiting
43
Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre Hospitalier Univer
Sherbrooke, Quebec, Canada, J1H 5N4
Actively Recruiting
Research Team
P
Pfizer CT.gov Call Center
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here